Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review
Sign Up to like & getrecommendations! Published in 2025 at "Archives of Gynecology and Obstetrics"
DOI: 10.1007/s00404-024-07849-9
Abstract: Metabolic disease, including obesity and type 2 diabetes, are amongst the most significant health issues facing women of reproductive age. To date, no antenatal weight management tools have reduced the risk of adverse health outcomes… read more here.
Keywords: use; obesity; pregnancy; prior pregnancy ... See more keywords
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Sign Up to like & getrecommendations! Published in 2018 at "Current Cardiology Reports"
DOI: 10.1007/s11886-018-1051-2
Abstract: Purpose of ReviewMimetics and analogs that extend the half-life of native glucagon-like peptide-1 (GLP-1), i.e., glucagon-like peptide-1 receptor agonists (GLP-1 RAs), at therapeutic doses, are indicated as adjuncts to diet and exercise, to improve glycemic… read more here.
Keywords: reduction; risk; glucagon like; glp ras ... See more keywords
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Current Diabetes Reports"
DOI: 10.1007/s11892-018-1043-z
Abstract: Purpose of ReviewGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of… read more here.
Keywords: patients type; risk; glp ras; receptor agonists ... See more keywords
Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01034-w
Abstract: The relative efficacy and safety of once-daily oral semaglutide vs. injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in subjects with type 2 diabetes (T2D) inadequately controlled on basal insulin were assessed using network meta-analysis (NMA).… read more here.
Keywords: semaglutide; glp ras; basal insulin; oral semaglutide ... See more keywords
Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01189-6
Abstract: Introduction Reducing dosing frequency may lower treatment burden and improve persistence and adherence. This retrospective, observational study assessed persistence and adherence in patients with type 2 diabetes (T2D) initiating once-weekly or daily injectable glucagon-like peptide-1… read more here.
Keywords: group; type diabetes; persistence adherence; glp ras ... See more keywords
Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control
Sign Up to like & getrecommendations! Published in 2021 at "Diabetology International"
DOI: 10.1007/s13340-021-00508-3
Abstract: Aims The efficacy of dulaglutide was assessed according to the pretreatments administered before the initiation of dulaglutide in patients with type 2 diabetes. Methods In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly)… read more here.
Keywords: group; type diabetes; daily glp; glp ras ... See more keywords
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Sign Up to like & getrecommendations! Published in 2024 at "European Psychiatry"
DOI: 10.1007/s40501-024-00331-y
Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for managing metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Beyond their metabolic benefits, GLP-1 RAs exhibit neuroprotective and psychotropic effects, potentially benefiting… read more here.
Keywords: glp ras; mental health; ras mental; systematic review ... See more keywords
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2021.1951702
Abstract: ABSTRACT Introduction Schizophrenia is a neuropsychiatric disorder that affects approximately 1% of individuals worldwide. There are no available medications to treat cognitive impairment in this patient population currently. Preclinical evidence suggests that glucagon-like peptide-1 receptor… read more here.
Keywords: schizophrenia; glp ras; glp; cognitive impairment ... See more keywords
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of epidemiology"
DOI: 10.1093/aje/kwac021
Abstract: Case reports and a pharmacovigilance analysis have linked glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with anaphylactic reactions, but real-world evidence for this possible association is lacking. Using databases from the United Kingdom (Clinical Practice Research… read more here.
Keywords: reaction; glp ras; risk anaphylactic; glucagon like ... See more keywords
Cardiovascular effects of incretins - focus on GLP-1 receptor agonists.
Sign Up to like & getrecommendations! Published in 2022 at "Cardiovascular research"
DOI: 10.1093/cvr/cvac112
Abstract: GLP-1 receptor agonists (GLP-1 RAs) have been used to treat patients with type 2 diabetes since 2005 and have become popular because of the efficacy and durability in relation to glycaemic control in combination with… read more here.
Keywords: receptor agonists; glp receptor; glp ras; type diabetes ... See more keywords
O-046 Obesity, implantation and early pregnancy - does GLP1 play a role?
Sign Up to like & getrecommendations! Published in 2025 at "Human Reproduction"
DOI: 10.1093/humrep/deaf097.046
Abstract: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are increasingly used to treat overweight/obesity and type 2 diabetes. However, little is known about the effect of GLP-1 RAs exposure during pregnancy. In a nationwide observational cohort… read more here.
Keywords: existing diabetes; glp; preterm birth; glp ras ... See more keywords